Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen-Reference-Cited by-同舟云学术

Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen

Published:2018-04 Issue:4 Volume:24 Page:429.e1-429.e5
ISSN:1198-743X
Container-title:Clinical Microbiology and Infection
language:en
Short-container-title:Clinical Microbiology and Infection

Author:

Werth B.J.,Jain R.,Hahn A.,Cummings L.,Weaver T.,Waalkes A.,Sengupta D.,Salipante S.J.,Rakita R.M.,Butler-Wu S.M.

Funder

Allergan

Merck

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference34 articles.

1. Origin, structure, and activity in vitro and in vivo of dalbavancin;Malabarba;J Antimicrob Chemother,2005

2. Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates;Biedenbach;Antimicrob Agents Chemother,2009

3. Dalvance™ Package Insert,2016

4. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin;Zhanel;Drugs,2010

5. A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection;Dunne;Clin Infect Dis,2016

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unraveling novel mutation patterns and morphological variations in two dalbavancin-resistant MRSA strains in Austria using whole genome sequencing and transmission electron microscopy;BMC Infectious Diseases;2024-09-02

2. Wireless Optogenetic Targeting Nociceptors Helps Host Cells Win the Competitive Colonization in Implant‐Associated Infections;Small Methods;2024-08

3. Genome-wide CRISPRi screens for high-throughput fitness quantification and identification of determinants for dalbavancin susceptibility in Staphylococcus aureus;mSystems;2024-07-23

4. Dalbavancin as suppressive therapy for implant-related infections: a case series with therapeutic drug monitoring and review of the literature;European Journal of Clinical Microbiology & Infectious Diseases;2024-05-16

5. Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection: A Multicenter Observational Study;Infectious Diseases and Therapy;2024-03